REST Study: Left Ventricular Regression European Study

Aortic Valve Stenosis Clinical Trial

Official title:

Left Ventricular Regression European Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00256165
• Other study ID #: CS04009TV
• Status: Completed
• Phase: Phase 4
• Start date: January 2006
• Est. completion date: July 2008

Study information

• Verified date: February 2019
• Source: Abbott Medical Devices
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to obtain data regarding the left ventricular mass (LVM) regression 6 months after the implant of an SJM Epic™ and SJM Epic™ Supra valve by comparing LVM regression measured with magnetic resonance imaging (MRI) to LVM regression measured with echocardiography (2-dimensional [2D] mandatory; 3-dimensional [3D] in sites where the technology is available).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: July 2008
• Est. primary completion date: July 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient requires, for the first time, isolated aortic valve replacement due to aortic stenosis or mixed aortic stenosis disease etiology when aortic stenosis is predominant and aortic regurgitation is mild.

• Patient is of legal age in the host country.

• Patient (or legal guardian) has signed a study specific informed consent form

Exclusion Criteria:

• Patient was previously operated on with any heart surgery including heart valve replacement or coronary artery bypass graft (CABG); or underwent any form of myocardial revascularization in the past (including stents), etc.

• Patient requires any concomitant heart surgery other than the isolated native aortic heart valve replacement and concomitant ascending aortic replacement (e.g not allowed are: multiple valve replacements or concomitant CABG, pacemaker insertions, or severe septal hypertrophy needing surgical excision, etc.)

• Patient has unstable angina

• Patient is in New York Heart Association functional class IV

• Patient has significant abnormality in wall motion

• Patient is affected by active endocarditis.

• Patient has a cardiac pacemaker or automatic implanted cardiac defibrillator

• Patient is affected by acute aortic dissection.

• Patient is in chronic and persistent atrial fibrillation

• Patient receives hemodialysis therapy

• Patient has a medical condition which contraindicates implantation of the SJM Epic and Epic™ Supra Porcine Bioprosthetic Heart Valve (e.g. renal failure or abnormal calcium metabolism).

• Patient has aneurysmal clips or carotid artery vascular stents

• Patient has a neurostimulator

• Patient has an implanted or external drug infusion device (e.g. insulin pump)

• Patient has a bone growth/fusion stimulator

• Patient has a cochlear, otologic, or ear implant

• Patients with severe claustrophobia in which medical sedation is contraindicated or unable to resolve anxiety sufficiently

• Patients with ocular foreign body (e.g. metal shavings)

• Patient is pregnant or nursing

Related Conditions & MeSH terms

• Aortic Valve Stenosis

Intervention

Device:
• Tissue valve
Aortic valve replacement

Locations

Country	Name	City	State
Germany	Städtlishes Klinikum Braunschweig	Braunschweig

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The comparison of left ventricular mass index (LVMI) at 6 months between echocardiogram (echo) and MRI in patients implanted with an Epic valve		At 6 months